Search Results for: CBL

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CSF1R colony stimulating factor 1 receptor
  • Other interleukin signaling
  • Transcriptional Regulation by VENTX
  • Imatinib
  • Sunitinib
  • ABT-869
  • 5-CYANO-FURAN-2-CARBOXYLIC ACID [5-HYDROXYMETHYL-2-(4-METHYL-PIPERIDIN-1-YL)-PHENYL]-AMIDE
  • 6-CHLORO-3-(3-METHYLISOXAZOL-5-YL)-4-PHENYLQUINOLIN-2(1H)-ONE
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Choriocarcinoma
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
CUBN cubilin
  • Cobalamin (Cbl, vitamin B12) transport and metabolism
  • Vitamin D (calciferol) metabolism
  • Defective AMN causes hereditary megaloblastic anemia 1
  • Defective CUBN causes hereditary megaloblastic anemia 1
  • HDL clearance
  • Hydroxocobalamin
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EIF5B eukaryotic translation initiation factor 5B
  • GTP hydrolysis and joining of the 60S ribosomal subunit
EPHA2 EPH receptor A2
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Dasatinib
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Regorafenib
  • Fostamatinib
EPHB6 EPH receptor B6
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib
EPOR erythropoietin receptor
  • Signaling by Erythropoietin
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Erythropoietin activates STAT5
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Darbepoetin alfa
  • Erythropoietin
  • Dibromotyrosine
  • Peginesatide
  • Methoxy polyethylene glycol-epoetin beta
  • Congenital polycythemia; Familial erythrocytosis (ECYT)
EPS8 epidermal growth factor receptor pathway substrate 8
F2RL1 F2R like trypsin receptor 1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FLOT1 flotillin 1
  • RIPK1-mediated regulated necrosis
  • Regulation of necroptotic cell death
  • Synaptic adhesion-like molecules
FLT3 fms related receptor tyrosine kinase 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • FLT3 mutants bind TKIs
  • STAT5 activation downstream of FLT3 ITD mutants
  • KW2449-resistant FLT3 mutants
  • semaxanib-resistant FLT3 mutants
  • crenolanib-resistant FLT3 mutants
  • gilteritinib-resistant FLT3 mutants
  • lestaurtinib-resistant FLT3 mutants
  • midostaurin-resistant FLT3 mutants
  • pexidartinib-resistant FLT3 mutants
  • ponatinib-resistant FLT3 mutants
  • quizartinib-resistant FLT3 mutants
  • sorafenib-resistant FLT3 mutants
  • sunitinib-resistant FLT3 mutants
  • tandutinib-resistant FLT3 mutants
  • linifanib-resistant FLT3 mutants
  • tamatinib-resistant FLT3 mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Negative regulation of FLT3
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling by CBL mutants
  • Sorafenib
  • Sunitinib
  • XL999
  • Tandutinib
  • ABT-869
  • Lestaurtinib
  • Midostaurin
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Gilteritinib
  • Brigatinib
  • Fedratinib
  • Amuvatinib
  • Quizartinib
  • Pexidartinib
  • Pralsetinib
  • Acute myeloid leukemia (AML)
FNBP1 formin binding protein 1
  • Clathrin-mediated endocytosis
FRS2 fibroblast growth factor receptor substrate 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
FYB1 FYN binding protein 1
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • Signal regulatory protein family interactions
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Triglyme
  • Fostamatinib
GRAP2 GRB2 related adaptor protein 2
  • Signaling by SCF-KIT
  • Generation of second messenger molecules
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CD28 co-stimulation
  • FLT3 Signaling
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
HCK HCK proto-oncogene, Src family tyrosine kinase
  • Nef and signal transduction
  • FCGR activation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • FLT3 signaling through SRC family kinases
  • 1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • Phosphonotyrosine
  • Quercetin
  • Bosutinib
  • Fostamatinib

Page 2 out of 7 pages